procaps group has experience in the development of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. we have direct presence in 13 countries in latin america and we have more than 5,000 collaborators working under a sustainable model. we develop, manufacture, and market over-the-counter (otc) and prescription drugs, nutritional supplements and high-potential clinical solutions.
Company profile
Ticker
PROC
Exchange
Website
CEO
Ruben Minski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PROC stock data
Latest filings (excl ownership)
6-K
Procaps Announces Formation of Strategic Committee to Explore Value Creation Alternatives
4 Mar 24
6-K
Report of Foreign Private Issuer
24 Jan 24
6-K
Report of Foreign Private Issuer
16 Jan 24
6-K
Report of Foreign Private Issuer
5 Jan 24
6-K
Unaudited Condensed Consolidated Interim Financial Statements
26 Dec 23
6-K
Procaps Group Reports Third Quarter 2023 Results
26 Dec 23
6-K
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
22 Nov 23
6-K
Procaps Appoints Sandra Sánchez y Oldenhage to Board of Directors
23 Oct 23
6-K
Procaps Group Announces the Expansion of its Oncology Portfolio
7 Sep 23
6-K
Unaudited Condensed Consolidated Interim Financial Statements
5 Sep 23
Latest ownership filings
SC 13D/A
Hoche Partners Pharma Holding S.A.
20 Feb 24
SC 13D/A
Hoche Partners Pharma Holding S.A.
12 Jan 24
SC 13G
International Finance Corp
14 Feb 22
SC 13D
SOGNATORE TRUST
12 Oct 21
SC 13D
Hoche Partners Pharma Holding S.A.
12 Oct 21
3
Alexandre Weinstein Manieu
12 Oct 21
3
Ruben Minski
8 Oct 21
3
Jose Minski
8 Oct 21
3
Initial statement of insider ownership
8 Oct 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
81.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.48 bn |
Total shares | 92.26 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sognatore Trust | 67.26 mm | $0.00 |
Hoche Partners Pharma Holding | 15.88 mm | $0.00 |
Balyasny Asset Management | 6.05 mm | $944.14 mm |
LMR Partners | 1.06 mm | $201.27 mm |
Davidson Kempner Capital Management | 547.60 k | $69.82 mm |
TENOR CAPITAL MANAGEMENT | 400.00 k | $75.96 mm |
Bluefin Capital Management | 316.09 k | $60.03 mm |
Caption Management | 242.32 k | $46.02 mm |
Union Square Park Capital Management | 200.00 k | $37.98 mm |
Walleye Capital | 87.80 k | $16.67 mm |
News
A Look Into Healthcare Sector Value Stocks
11 Mar 24
5 Value Stocks In The Healthcare Sector
4 Mar 24
Procaps Announces Formation Of Strategic Committee To Explore Value Creation Alternatives
4 Mar 24
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday
13 Feb 24
5 Value Stocks To Watch In The Healthcare Sector
5 Feb 24